Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)		Ċ
·		Lori et	al.

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	В	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	C	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	E	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB- CLASS	
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn			
*	M	W O 87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood
		Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1
	i.	Replication,"
		Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 1 of 6				
L. E. Crane	09/18/04	¥: Reference not presently available.				
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)						

09/756,411 - PTO-892 Copy for [] FILE (APPLICANT Attachment to P. N. 09202004

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
·	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

		Other References (Including Author, Title, Date, Pertinent Pages, etc.)					
*	\mathbf{S}^{\dagger}	Biochemicals/Organic Compounds for Research and Diagnostic Reagents,					
		Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.					
*	T†	Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in					
		OM-10.1 Cells,"					
		Antiviral Chemistry & Chemotherapy, 4(1), 55-63 (1993).					
*	U †	Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on					
		the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log					
		Phase and Contact-Inhibited Human Fibroblasts,"					
		Molecular Pharmacology, 28(6), 574-580 (1985); see p. 578 in particular.					
*	V	Licastro et al., "Inhibition of Polymerases-α and -ß Completely Blocks					
		DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells,"					
		Biochemical Biophysical Res. Comm., 132(3), 929-933 (Nov. 15, 1985).					
*	\mathbf{W}^{\dagger}	Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-					
		Dideoxyguanosine,"					
		AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).					
*	X	R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I,"					
		Genetic Engineering News, September 1, 1992, pp. 4-6.					
*	Y	R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II,"					
		Genetic Engineering News, September 15, 1992, pp. 4-5.					
*	\mathbf{Z}	"Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men,"					
		Morbidity Mortality Weekly Rept., Vol. 30(25), Centers for Disease					
		Control, July 3, 1981, pp. 305-308.					

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

		page 2 of 6					
L. E. Crane The Cane	09/18/04	¥: Reference not presently available.					
*A copy of this reference is not being furnished with this office action.							
(See Manual	of Patent Examining	g Procedure, Section 707.05(a).)					

09/756,411 - PTO-892 Copy for [] FILE APPLICANT Attachment to P. N. 09202004

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

		Other References (Including Author, 11tle, Date, Pertinent Pages, etc.)					
*	RA†	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a					
		Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS),"					
		Science, 220, 868-871 (1983).					
*	SA	Fauci (I), "The Human Immunodeficiency Virus: Infectivity and					
	S A	Mechanisms of Pathogenesis,"					
		Science, 239, 617-622 (February 1988).					
*	TA	Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus					
		Disease: Implications for Therapy,"					
	,	Science, 262, 1011-1018 (November 12, 1993).					
*	UA	Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular					
		Analysis Reveals a Labile, Latent Viral Structure,"					
		Cell, 61, 213-222 (April 20, 1990).					
*	VA	Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus					
		Reservoir in HIV-1 Infection,"					
		Science, 254, 233-237 (October 18, 1991).					
*	WA	Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is					
		a T Cell that Maintains Expression of CD4,"					
		Science, 245, 305-308 (July, 1989).					
*	XA	Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human					
		Immunodeficiency Virus Type 1 RNA,"					
		Journal of Infectious Diseases, 164, 1051-1057 (December, 1991).					
*	VA	Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection,"					
	1 1.						
<u></u>	<u> </u>	New England Journal of Medicine, 328(23), 1686-1695 (June 10, 1993).					

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 3 of 6					
L. E. Crane // E. Cano	09/18/04	¥: Reference not presently available.					
*A copy of this reference is not being furnished with this office action.							
(See Manual	of Patent Examining	ng Procedure, Section 707.05(a).)					

09/756,411 - PTO-892 Copy for [] FILE APPLICANT Attachment to P. N. 09202004

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

		other restricted (metading reduct, rate, Bate, retainent rages, etc.)
*	ZA†	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric
		Assay for the Detection of Anti-HIV Compounds,"
		Journal of Virological Methods, 20, 309-321 (1988).
*	RB	Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-
		dideoxythymidine (Zidovudine) and Related Dideoxynucleosides,"
		New England Journal of Medicine, 321(11), 726-738 (September 14, 1989).
*	SB [†]	Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug
		Resistance to Optimize Therapy,"
		Nature, 361, 650-654 (1993).
*	TR	Lori et al.(III), "Hydroxyurea as an Inhibitor of Human Immunodeficiency
		Virus-Type 1 Replication,"
		Science, 266, 801-805 (November 4, 1994).
*	UB†	Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-
	OB.	fluorothymidine and 3'-Azidothymidine in CEM Cells,"
		European Journal of Biochemistry, 186, 689-694 (1989).
*	X 7 YD +	Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as
	VB [†]	-
		Active Agents Against HIV,"
		Journal of Medicinal Chemistry, 33(3), 978-985 (1990).
*	WB [†]	Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision;
		Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repai</u> et al. <u>r and</u>
		Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL
		Press, Oxford, England, 1984, pp. 13-33.

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER //	DATE	page 4 of 6
L. E. Crane / L. Vane	09/18/04	¥: Reference not presently available.
- ·		ng furnished with this office action. g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)	Lori et	al.

_		Other References (Including Author, Title, Date, Pertinent Pages, etc.)
*	XB	Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected
		Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea],"
		Lancet, 350(9078), 635-636 (August 30, 1997).
*	YB	Schoofs, "The Berlin Patient,"
1.5		The New York Times Magazine, pp. 32-35, June 21, 1998.
*	$\mathbf{Z}\mathbf{B}^{\dagger}$	Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on
		the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse
		Transcriptase Inhibitors,"
		Pharmacology and Therapeutics, 87(2-3), 175-187 (2000).††
*	\mathbf{RC}^{\dagger}	Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human
		Immunodeficiency Virus Type 1 Potency of 2'-β-Fluoro-2',3'-
		dideoxyadenosine in Peripheral Blood Mononuclear Cells,"
		Biochemical Pharmacology, 50(2), 274-276 (1995).††
*	SC^{\dagger}	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically
		Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine,"
		Molecular Pharmacology, 37, 590-596 (1990).
	TC [†]	Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-
i I		dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and
l		Chemical Stability over 2',3'-Dideoxyadenosine,"
		Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).
*	UC	Gao et al. (III), "Differential Phosphorylation of Azidothymidine,
		Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral
		Blood Mononuclear Cells,"
		Journal of Clinical Investigations, 91(5), 2326-2333 (May, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER	DATE	page 5 of 6
L. E. Crane / Come	09/18/04	¥: Reference not presently available.
		ng furnished with this office action. g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
· ·	09/756,411	1623	09202004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

*	$\mathbf{V}\mathbf{C}^{\dagger}$	Sumpter et al., "In Vivo Examination of Hydroxyurea and the Novel
		Ribonucleotide Reductase Inhibitors Trimidox and Didox in Combination
Į.		with the Reverse Transcriptase Inhibitor Abacavir: Suppression of
		Retrovirus-induced Immunodeficiency,"
		Antiviral Research, 62, 111-120 (2004).††
*	WC	Palmer et al., "Hydroxyurea Enhances the Activities of Didanosine,
*	WC	Palmer et al., "Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and
*	WC	
*	WC	9-[2-(Phosphonylmethoxy)ethyl]adenine, and

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER
L. E. Crane

*A copy of this reference is not being furnished with this office action.

(See Manual of Patent Examining Procedure, Section 707.05(a).)

^{††} Copy kindly supplied by Applicant.